Sort by
Refine Your Search
-
Country
-
Employer
- SciLifeLab
- Karolinska Institutet
- University of Antwerp
- University of Bergen
- University of Copenhagen
- Uppsala University
- Uppsala universitet
- ;
- ; Newcastle University
- Amsterdam UMC
- Conway Institute of Biomolecular & Biomedical Research
- ETH Zurich
- KU Leuven
- Newcastle University
- Radboud University
- University Paris Cité
- Vrije Universiteit Amsterdam (VU)
- 7 more »
- « less
-
Field
-
at Department of Pharmacy Faculty of Health and Medical Sciences University of Copenhagen We are offering a three-year interdisciplinary PhD fellowship in cutaneous drug delivery, starting
-
PhD Studentship: Cyclic peptide discovery for intracellular protein targets Award Summary 100% home fees covered, and a minimum tax-free annual living allowance of £19,237 (2024/25 UKRI rate), plus
-
working at the interface of chemistry, biology and medicine, and have interest in therapeutics discovery. Opportunities to visit AstraZeneca for placements during the PhD will be provided to gain industrial
-
, drug discovery and development for rare diseases. Our innovative and ambitious joint-PhD program will train highly qualified young scientists in new scientific and technological knowledge. At the end
-
critical challenges in the field of organoid technologies for disease modelling, drug discovery and development for rare diseases. Our innovative and ambitious joint-PhD program will train highly qualified
-
of the PhD project is to develop computational approaches to identify small molecule and peptide ligands that target therapeutically relevant receptors, with the vision to accelerate the drug discovery process
-
the drug discovery process. The project will be focused on addressing several challenges in structure-based drug design using artificial intelligence. Recently developed techniques for the prediction
-
substantially. A major obstacle in RNA-targeting drug discovery is the lack of knowledge on how to obtain drug-like RNA ligands. The main goal of this project is therefore to establish a blueprint on how to
-
be modulated and thus the size of the druggable genome can be increased substantially. A major obstacle in RNA-targeting drug discovery is the lack of knowledge on how to obtain drug-like RNA ligands
-
integration, analysis, visualization, and data interpretation for patient stratification, discovery of biomarkers for disease risks, diagnostics, drug response assessment and monitoring of health. The precision